Avizakimab

DB18842InvestigationalProtein Based Therapies

Avizakimab is under investigation in clinical trial NCT03371251 (Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care).

Mechanism: Pharmacologically active on Interleukin-21
Curator reviewed
Also known as: Immunoglobulin g1 (251-tyrosine,253-threonine,255-glutamic acid), anti-(human interleukin 21) (human-mus musculus monoclonal bos161721 .gamma.1-chain), disulfide with human-mus musculus monoclonal bos161721 .kappa.-chain, dimer
Code names: BOS-161721

Resolves to

Compound

UNII4H3BBE5WVKCAS2229685-51-0

Targets

Q9HBE4IL21

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Avizakimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account